Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions: Glutathione, N-Acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections, Hypercholesterolemia, Glucose Intolerance
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Atherosclerosis, Hypercholesterolemia
Interventions: Statins, HMG CoA; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years to 99 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Hyperlipidemia, Obesity
Interventions: Physical Activity Group, Standard Care Group; Behavioral · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Charleston, South Carolina • Columbia, South Carolina

Conditions: ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran Sodium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 141
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more

Conditions: Hypercholesterolemia
Interventions: Colesevelam Hydrochloride, Ezetimibe, Simvastatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 7
States / cities: San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Hypertension and Hyperlipidemia
Interventions: HTN and Medication Adherence; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesteremia
Interventions: Gemcabene, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • Beverly Hills, California • Huntington Park, California + 19 more

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Different amount of phytosterols are added into diets; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Ezetimibe; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 68
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 61 more

Conditions: HIV Infections, Hyperlipidemia
Interventions: Atorvastatin; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 10 Years to 23 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 11
States / cities: Aurora, Colorado • Miami, Florida • Tampa, Florida + 7 more

Conditions: Hypercholesterolemia, Coronary Artery Disease, Dyslipidemia, Hypertension
Interventions: Direct-to-patient tailored cardiovascular risk message system; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 79 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Diabetes, Hypertension, Hyperlipidemia
Interventions: Exercise, Reduced Calorie Diet, Weight Maintenance Diet; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 65 Years and older
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 17
States / cities: Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more

Conditions: Cardiovascular Disease
Interventions: GSK2212836; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hyperlipidemia, Hypertension, Obesity
Interventions: Nutritional counseling, Walking program, Simple pedometer, Enhanced pedometer; Behavioral · Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more

Conditions: Homozygous Familial Hypercholesterolemic
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: NK-104-CR, Livalo® IR, Placebo (for NK-104-CR), Placebo (for Livalo® IR); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 69
States / cities: Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more

Conditions: Hypercholesterolemia
Interventions: PRO-040201, Placebo; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypercholesterolemia
Interventions: REGN727(SAR236553); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Knoxville, Tennessee

Conditions: Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia, Atherosclerotic Disease
Interventions: Alirocumab 150 MG/ML [Praluent]; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
Interventions: Lifestyle counseling and coaching; Behavioral
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Search by objective public record fields.

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

Metabolic Abnormalities in HIV Infected and Uninfected Young Women

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Gamification and Medication Adherence (GAME Adherence)

A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

Addition of Phytosterols to a Low Phytosterol Diet

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

Tailored Communication to Reduce Cardiovascular Risk

Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

Veterans Walk for Health Study

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Alirocumab in Patients on a Stable Dialysis Regimen

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients